

ISSUE @ A GLANCE



Unresolved issues of anticoagulation in atrial fibrillation: age, BMI, reduced dose, and ethnicity
T.F. Lüscher

1477

CardioPulse

Breaking Down the Hierarchy of Medicine
M.S. Panhwar and A. Kalra

1482

Biomarkers and Cardiovascular Risk Stratification
P.T. Matusik

1483

Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines for Norway
S.E. Kjeldsen, T. A. Aksnes, R. Mo, and T. O. Klemsdal

1485

Acute Coronary Syndromes in Cancer Patients
A. Guha, A.K. Dey, H. Jneid, and D. Addison

1487

Dr Aram J. Mirza and cardiology in Kurdistan
A.H. Frangieh

1490

CLINICAL RESEARCH

Atrial fibrillation

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials
K.-L. Wang, R.D. Lopes, M.R. Patel, H.R. Büller, D.S.-Y. Tan, C.-E. Chiang, and R.P. Giugliano

1492

Editorial

On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?
D. Atar and I. Grundvold

1501

Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities
T.-F. Chao, G.Y.H. Lip, Y.-J. Lin, S.-L. Chang, L.-W. Lo, Y.-F. Hu, T.-C. Tuan, J.-N. Liao, F.-P. Chung, T.-J. Chen, and S.-A. Chen

1504


Editorial

Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities
S. Z. Goldhaber and G. Piazza

1515

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
T.-F. Chao, S.-A. Chen, C.T. Ruff, R.A. Hamerschock, M.F. Mercuri, E.M. Antman, E. Braunwald, and R.P. Giugliano

1518



Editorial

Stroke prevention in AF: Of Asians and non-Asians

J. Steffel and J.W. Eikelboom

1528

When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study

H.T. Yu, J. Shim, J. Park, T.-H. Kim, J.-S. Uhm, J.-Y. Kim, B. Joung, M.-H. Lee, Y.-H. Kim, and H.-N. Pak

1531

Editorial

Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation

J.T. Bunch and S.C. Woller


1538

Thrombosis and antithrombotic therapy

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

G. Boriani, C.T. Ruff, J.F. Kuder, M. Shi, H.J. Lanz, H. Rutman, M.F. Mercuri, E.M. Antman, E. Braunwald, and R.P. Giugliano

1541



Editorial

The evolving obesity paradigm story: from heart failure to atrial fibrillation

S. von Haehling, W. Doehner, and S.D. Anker

1550



Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

J. Oldgren, P.G. Steg, S.H. Hohnloser, G.Y.H. Lip, T. Kimura, M. Nordaby, M. Brueckmann, E. Kleine, J.M. ten Berg, D.L. Bhatt, and C.P. Cannon; on behalf of the RE-DUAL PCI Steering Committee and Investigators

1553

Editorial

Atrial fibrillation, with ACS and PCI: walking a tightrope

R. Mehran, D.N. Kalkman, and D.J. Angiolillo

1563

DISCUSSION FORUM

Where's the bleed? A response to Piccini *et al.*: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

P. Bamford and J. Rogers

1567

Reply to letter by Bamford *et al.* regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

J.P. Piccini, J. Garg, A. Hellkamp, K.S. Pieper, and M.R. Patel; for the ROCKET AF Steering Committee & Investigators

1568

Challenges in clinical decision-making on concomitant drug therapies in patients with atrial fibrillation taking oral anticoagulants

J. Steffel and T.S. Potpara

1569



Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants

F.-X. Mathy, E. Dohin, F. Bonfitto, and B. Pelgrims

1571

Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs

S. Kurt, O. Sumbul, and D. Aksoy

1572

CARDIOVASCULAR FLASHLIGHTS

A rare case of percutaneous exclusion of a huge aortic pseudo-aneurysm following aortic bio prosthetic endocarditis: key role of 3D echo-fluoro fusion imaging

M. Gavazzoni, A. Pozzoli, C.A. Mestres, and F. Maisano

1573

Cardiac tamponade after pulmonary endarterectomy: mind the left side...

L. Bibas, M. Al-Kalbani, M. de Perrot, and G. Douflé

1575



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org